ADA 2026: New GLP-1 Oral Drug, Semaglutide-Amylin Combo, and Chinese Mazdutide Data Highlighted

An interview with Dr. Rita Kalyani, the ADA's chief scientific and medical officer, discussing key research presented at the ADA 2026 Scientific Sessions in New Orleans. Topics include an investigational oral GLP-1 receptor agonist for diabetes, a combination injection of semaglu